Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharmaceutical Partners (CPRX)
:CPRX
CPRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.47 - $26.16
Previous CloseN/A
Volume328.11K
Average Volume (3M)1.40M
Market Cap
$2.96B
Enterprise Value$2.12B
Total Cash (Recent Filing)$6.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)18.6
Beta0.93
Next Earnings
May 07, 2025EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.31
Shares Outstanding121,959,175
10 Day Avg. Volume763,854
30 Day Avg. Volume1,398,768
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.02
Enterprise Value/Ebitda9.91
Forecast
1Y Price Target
$34.00Price Target Upside39.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Market PositionCatalyst is well positioned to capitalize on the cancer associated LEMS opportunity for Firdapse.
Revenue GrowthAgamree revenues continue to support a strong launch, with 4Q24 revenue indicating increasing momentum.
Bears Say
Competitive PressureFycompa sales are likely to be negatively impacted this year by generic entry in May.
Generic CompetitionFycompa sales are likely to be negatively impacted this year by generic entry in May.
---
Ownership Overview
6.23% Insiders
18.17% Mutual Funds
2.00% Other Institutional Investors
50.21% Public Companies and
Individual Investors
CPRX FAQ
What was Catalyst Pharmaceutical Partners’s price range in the past 12 months?
Catalyst Pharmaceutical Partners lowest stock price was $14.47 and its highest was $26.16 in the past 12 months.
What is Catalyst Pharmaceutical Partners’s market cap?
Catalyst Pharmaceutical Partners’s market cap is $2.96B.
When is Catalyst Pharmaceutical Partners’s upcoming earnings report date?
Catalyst Pharmaceutical Partners’s upcoming earnings report date is May 07, 2025 which is in 5 days.
How were Catalyst Pharmaceutical Partners’s earnings last quarter?
Catalyst Pharmaceutical Partners released its earnings results on Feb 26, 2025. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.339 by $0.101.
Is Catalyst Pharmaceutical Partners overvalued?
According to Wall Street analysts Catalyst Pharmaceutical Partners’s price is currently Undervalued.
Does Catalyst Pharmaceutical Partners pay dividends?
Catalyst Pharmaceutical Partners does not currently pay dividends.
What is Catalyst Pharmaceutical Partners’s EPS estimate?
Catalyst Pharmaceutical Partners’s EPS estimate is 0.34.
How many shares outstanding does Catalyst Pharmaceutical Partners have?
Catalyst Pharmaceutical Partners has 121,959,175 shares outstanding.
What happened to Catalyst Pharmaceutical Partners’s price movement after its last earnings report?
Catalyst Pharmaceutical Partners reported an EPS of $0.44 in its last earnings report, beating expectations of $0.339. Following the earnings report the stock price went up 5.248%.
Which hedge fund is a major shareholder of Catalyst Pharmaceutical Partners?
Currently, no hedge funds are holding shares in CPRX
---
Catalyst Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.00 (39.98% Upside)
$34.00 (39.98% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.39%
12-Months-Change
Fundamentals
Return on Equity
29.38%
Trailing 12-Months
Asset Growth
81.07%
Trailing 12-Months
Company Description
Catalyst Pharmaceutical Partners
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
---
CPRX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and successful product launches, particularly with AGAMREE and FIRDAPSE, supported by a strong financial position and favorable patent resolution. However, there are challenges with anticipated revenue decline for FYCOMPA due to patent expiry, increased SG&A expenses, and expected impacts from the Inflation Reduction Act.Read More>---
CPRX Stock 12 Month Forecast
Average Price Target
$34.00
▲(39.98% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Merus
―
Crispr Therapeutics AG
―
Rhythm Pharmaceuticals
―
---